The GLP is committed to full transparency. Download and review our 2019 Annual Report

As trade talks progress, China may slow already lengthy approval process for US biotech crops

| | March 8, 2019
trade war
Image Credit: Gapping World
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

China may agree to buy more U.S. agriculture commodities and lift onerous trade barriers in the ongoing talks, but unless negotiators can agree on an effective way to make sure the Chinese live up to their promises, any final deal would be worthless.

“I think that whatever we agree to as a matter of substance, enforcement is very important because we have been snookered by the Chinese in past agreements….” Senate Finance Committee Chairman Chuck Grassley said March 5]. “In final negotiations, enforcement is the last big thing for our government to work out, and our negotiators are on top of it.”

Related article:  Led by Nigeria, Africa opening door to genetically modified crop cultivation

One of the ag policy issues U.S. negotiators have been pushing especially hard on is China’s opaque and lengthy biotech trait approval system. [U.S. Trade Representative Robert] Lighthizer said [the last week of February] he has made it a priority of his to get reform, but signs from inside China show that the country is going in the opposite direction.

The Chinese Ministry of Agriculture and Rural Affairs has recently revised rules to “impose additional in-country trials and studies on new biotech events as part of the dossier submission process,” according to a new analysis by USDA’s Foreign Agricultural Service.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend